The estimated Net Worth of Marvin L White is at least $1.18 Million dollars as of 2 March 2024. Mr White owns over 22,501 units of Aptevo Therapeutics Inc stock worth over $24,342 and over the last 14 years he sold APVO stock worth over $293,000. In addition, he makes $859,495 as Pres und CEO & Director at Aptevo Therapeutics Inc.
Sign up
Mr White APVO stock SEC Form 4 insiders trading
Mr has made over 12 trades of the Aptevo Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 22,501 units of APVO stock worth $8,123 on 2 March 2024.
The largest trade he's ever made was selling 100,000 units of Aptevo Therapeutics Inc stock on 19 March 2018 worth over $293,000. On average, Mr trades about 6,776 units every 76 days since 2010. As of 2 March 2024 he still owns at least 67,430 units of Aptevo Therapeutics Inc stock.
You can see the complete history of Mr White stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Marvin L. White biography
Marvin L. White is the Pres, CEO & Director at Aptevo Therapeutics Inc.
What is the salary of Mr White?
As the Pres und CEO & Director of Aptevo Therapeutics Inc, the total compensation of Mr White at Aptevo Therapeutics Inc is $859,495. There are no executives at Aptevo Therapeutics Inc getting paid more.
How old is Mr White?
Mr White is 59, he's been the Pres und CEO & Director of Aptevo Therapeutics Inc since . There are 1 older and 1 younger executives at Aptevo Therapeutics Inc. The oldest executive at Aptevo Therapeutics Inc is Dr. Jane A. Gross, 63, who is the Sr. VP & Chief Scientific Officer.
What's Mr White's mailing address?
Marvin's mailing address filed with the SEC is 2401 4TH AVENUE, 1050, SEATTLE, WA, 98121.
Insiders trading at Aptevo Therapeutics Inc
Over the last 8 years, insiders at Aptevo Therapeutics Inc have traded over $17,157,676 worth of Aptevo Therapeutics Inc stock and bought 1,998,342 units worth $25,387,921 . The most active insiders traders include Kevin Ctang Capital Managem..., Fuad El Hibri und Daniel Abdun Nabi. On average, Aptevo Therapeutics Inc executives and independent directors trade stock every 38 days with the average trade being worth of $22,185. The most recent stock trade was executed by So Young Kwon on 8 August 2024, trading 213 units of APVO stock currently worth $77.
What does Aptevo Therapeutics Inc do?
aptevo therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market. we leverage the innovative adaptir™ platform technology, a unique approach to cancer immunotherapy, to improve outcomes for cancer patients. based in seattle, washington, the company is proud of its empowering work environment, entrepreneurial culture, and proprietary platform technology. as a result, aptevo has been able to attract some of the most innovative minds in the field. many of our team members have notable experience with other pioneering biotech companies including trubion, zymogenetics, immunex, dendreon, and vlst. at aptevo therapeutics, our core values of ownership and collaboration—combined with a history of innovation, dedication, and development—are positioning aptevo therapeutics to develop the science of what’s next in biotechnology.
What does Aptevo Therapeutics Inc's logo look like?
Complete history of Mr White stock trades at Aptevo Therapeutics Inc, Emergent Biosolutions Inc und Washington Prime Inc
Aptevo Therapeutics Inc executives and stock owners
Aptevo Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Marvin L. White,
Pres, CEO & Director -
Jeffrey G. Lamothe,
Sr. VP, CFO & Treasurer -
Dr. Jane A. Gross,
Sr. VP & Chief Scientific Officer -
Dr. Fatih M. Uckun M.D., Ph.D.,
Chief Clinical Advisor & Consultant -
SoYoung Kwon J.D., LL.M.,
Sr. VP, Gen. Counsel, Corp. Affairs & HR -
Censia Pottorf,
VP of HR -
Heather Boussios,
Acting Gen. Counsel & Assistant Sec. -
Stacey Jurchison,
Sr. Director of Investor Relations & Corp. Communications -
Scott C Stromatt,
Chief Medical Officer and SVP -
Fuad El Hibri,
Director -
Bio Solutions Inc. Emergent,
10% owner -
Daphne Taylor,
SVP, CFO -
Zsolt Harsanyi,
-
John Niederhuber,
-
Marvin L White,
President and CEO -
Daniel Abdun Nabi,
-
Grady Iii Grant,
-
Shawnte Mitchell,
SVP, GC and Corporate Affairs -
Michael Adelman,
SVP, Commercial Operations -
Jeffrey G. Lamothe,
EVP, COO -
Jane A Gross,
SVP & Chief Scientific Officer -
Randy Joe Maddux,
SVP of Operations, CMO -
Barbara Lopez Kunz,
-
So Young Kwon,
SVP, GC, BD & Corp Affairs -
Kevin Ctang Capital Managem...,